Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
Xiaofen Li,
No information about this author
Nan Zhou,
No information about this author
Yang Yu
No information about this author
et al.
Cancer Science,
Journal Year:
2024,
Volume and Issue:
115(7), P. 2371 - 2383
Published: April 18, 2024
Abstract
Biliary
tract
cancer
(BTC)
is
a
highly
aggressive
malignancy
with
limited
second‐line
therapy.
We
conducted
this
phase
2
trial
to
evaluate
the
efficacy
and
safety
of
nab‐paclitaxel
plus
sintilimab
in
advanced
BTC.
Histologically
confirmed
BTC
patients
documented
disease
progression
after
first‐line
chemotherapy
were
enrolled.
Subjects
received
125
mg/m
on
days
1
8
200
mg
day
1,
administered
every
3
weeks.
The
primary
end
point
was
objective
response
rate
(ORR).
secondary
points
progression‐free
survival
(PFS),
overall
(OS),
adverse
reactions.
Simultaneously,
next‐generation
sequencing,
programmed
cell
death
ligand
immunohistochemistry
multiplex
immunofluorescence
tumor‐infiltrating
lymphocytes
applied
explore
potential
biomarkers.
Twenty‐six
subjects
consecutively
ORR
26.9%
(7/26),
including
two
complete
responses
five
partial
responses,
which
met
point.
control
61.5%
(16/26).
median
PFS
169
(about
5.6
months,
95%
confidence
interval
[CI]
60–278
days).
OS
442
14.7
CI
298–586
Grade
treatment‐related
events
(TRAEs)
mainly
anemia
(27%),
leukopenia
(23%),
neutropenia
(19%),
peripheral
sensory
neuropathy
(8%).
No
grade
4
or
5
TRAEs
occurred.
Biomarker
analysis
suggested
that
positive
PD‐L1
high
proportions
CD8
+
T‐cell
infiltration
correlated
improved
clinical
outcome.
Nab‐paclitaxel
potentially
effective
tolerable
regimen
for
deserves
be
studied
large‐scale
trials.
status
T
might
promising
biomarkers
prediction.
Language: Английский
Comparison of treatment models for single primary advanced gallbladder cancer
Rongxuan Li,
No information about this author
Xiaohong Chen,
No information about this author
Bingchen Wang
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 13, 2024
Purpose
Treatment
for
advanced
gallbladder
cancer
(GBC)
remains
controversial,
with
various
recommendations
regarding
the
choice
and
combination
of
surgery
adjuvant
therapy.
The
present
article
is
targeting
exploration
optimal
treatment
models
GBC.
Methods
AJCC
(American
Joint
Committee
on
Cancer,
8th
edition)
stage
III
IV
GBC,
were
defined
as
Patients
GBC
identified
using
Surveillance,
Epidemiology,
End
Results
(SEER)
database
departmental
cohort.
Because
most
representative,
only
adenocarcinoma
(GBAC)
patients
selected.
Based
their
surgical
status
(No,
Non-radical
Radical
surgery),
chemotherapy
(Chemotherapy,
No
chemotherapy),
radiotherapy
(Radiotherapy,
radiotherapy),
categorized.
For
purposes
evaluating
outcomes
determining
risk
element
cancer-specific
survival
(CSS),
Cox
regression
analysis
was
applied.
Kaplan-Meier
curves
used
before
after
adjusting
covariates,
log-rank
tests
to
analyze
discrepancies
between
curves.
Immunotherapy
analyzed
clinical
data
from
Finally,
compensate
limitations
database,
a
review
examines
progress
in
5,154
aged
over
18
years
solitary
primary
SEER
database.
In
patients,
model
has
emerged
significant
prognostic
factor.
“Radical
+
Chemotherapy
Radiotherapy”
maximally
improved
CSS
while
“No
radiotherapy”
had
lowest
CSS.
conclusions
supported
even
subgroup
by
stage.
efficacy
immunotherapy
demonstrated
cohort
analysis.
Additionally,
this
provides
comprehensive
overview
recent
advancements
emerging
strategies.
Conclusion
Even
when
cannot
be
pursued,
providing
combinations
treatments
whenever
possible
always
beneficial
survival.
Language: Английский